The functional domains in p53 family proteins exhibit both common and distinct properties

p53 is a sequence-specific transcription factor that functions to transactivate genes that mediate cell cycle arrest, DNA repair, apoptosis, and other p53-dependent activities. In 1997 and 1998, p73 and p63, respectively, were identified and emerged as p53 homologues (reviewed by Yang et al.). The p53 family proteins share significant similarity at the aminoacid level within three domains: the transcriptional activation domain (AD), the sequence-specific DNA-binding domain (DBD), and the tetramerization domain (TD) (Figure 1a). Like p53, both p63 and p73 bind to the canonical p53-responsive element and transactivate p53 target genes (reviewed by Harms et al.). Unlike p53, the genes encoding p63 and p73 are rarely mutated in human cancer and knockout mice demonstrate developmental defects rather than a propensity for tumor formation (reviewed by Yang et al.). However, recent evidence suggests that p63 and p73 do indeed play a role in tumor suppression since heterozygous p63 and p73 mice are prone to tumor formation. Thus, the p53 family proteins possess both common as well as nonoverlapping functions. At the 12th International p53 Workshop, we and others presented data identifying the functional domains in the p53 family proteins required for transcriptional activity, cell cycle arrest, and apoptosis (reviewed by Braithwaite et al.). As each domain plays an integral role in facilitating the differential functions of these transcription factors, here, we discuss the common and distinct properties of the transcriptional ADs, the DBD, nuclear localization and nuclear export signals (nuclear localization signal (NLS) and nuclear export signals (NES)), the TD, the basic domain (BD) that is present in p53 but not in p63 or p73, and the sterile-a-motif (SAM) domain that is present in some p63 and p73 isoforms but is lacking in p53.

[1]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[2]  A. Nakagawara,et al.  UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination , 2005, Oncogene.

[3]  J. Royds,et al.  The p53 story: layers of complexity. , 2005, Carcinogenesis.

[4]  M. Clarke,et al.  The nuclear import of p53 is determined by the presence of a basic domain and its relative position to the nuclear localization signal , 1999, Oncogene.

[5]  W. Deppert,et al.  A Novel Human p53 Isoform Is an Essential Element of the ATR-Intra-S Phase Checkpoint , 2005, Cell.

[6]  Xinbin Chen,et al.  p63α and ΔNp63α can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes , 2001, Oncogene.

[7]  M. Gostissa,et al.  KeePin’ the p53 Family in Good Shape , 2004, Cell cycle.

[8]  S. Berger,et al.  Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity , 1997, Oncogene.

[9]  T. Davison,et al.  Characterization of the oligomerization defects of two p53 mutants found in families with Li–Fraumeni and Li–Fraumeni-like syndrome , 1998, Oncogene.

[10]  Lennart Nilsson,et al.  Thermal unfolding simulations of a multimeric protein—Transition state and unfolding pathways , 2005, Proteins.

[11]  C. Prives,et al.  Covalent and noncovalent modifiers of the p53 protein , 1999, Cellular and Molecular Life Sciences CMLS.

[12]  M. Oren,et al.  The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.

[13]  P. Chène,et al.  The role of tetramerization in p53 function , 2001, Oncogene.

[14]  A. Yang,et al.  Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. , 2005, Cancer cell.

[15]  A. Levine,et al.  Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Eccles,et al.  The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions , 2003, Oncogene.

[17]  Xinbin Chen,et al.  p73 can suppress the proliferation of cells that express mutant p53 , 2003, Oncogene.

[18]  Y. Xiong,et al.  A p53 Amino-Terminal Nuclear Export Signal Inhibited by DNA Damage-Induced Phosphorylation , 2001, Science.

[19]  B. Vogelstein,et al.  Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication , 1991, Cell.